Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04944992 · ClinicalTrials.gov registry record · Phase 2
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT04944992 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 145 participants.
The verdict
NCT04944992, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Interventions
- DRUG Efinopegdutide 20 mg/mL
- DRUG Semaglutide 1.34 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04944992
The ClinicalTrials.gov registry entry for NCT04944992 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Efinopegdutide 20 mg/mL is the first listed.
NCT04944992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04944992 about?
NCT04944992 is a clinical study titled "A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)". The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relativ...
What is the current status of trial NCT04944992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2021-08-04. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04944992?
The interventions under investigation include: Efinopegdutide 20 mg/mL (DRUG), Semaglutide 1.34 mg/mL (DRUG).
Who is sponsoring clinical trial NCT04944992?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.